{"id":1688,"date":"2022-08-05T09:00:00","date_gmt":"2022-08-05T07:00:00","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/annualreport\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/"},"modified":"2023-05-19T17:52:08","modified_gmt":"2023-05-19T17:52:08","slug":"ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/","title":{"rendered":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat des actions d\u2019Epizyme, Inc. au 11 ao\u00fbt 2022"},"content":{"rendered":"<ul type=\"disc\">\n<li style=\"margin-top:5pt;margin-bottom:2.25pt\"><strong>Cette extension permettra de satisfaire la condition HSR, comme le pr\u00e9voit l\u2019Accord de Fusion.<\/strong><\/li>\n<li style=\"margin-top:5pt;margin-bottom:2.25pt\"><strong>Les actionnaires d\u2019Epizyme sont invit\u00e9s \u00e0 apporter leurs actions \u00e0 l\u2019offre d\u00e8s aujourd\u2019hui.<\/strong><\/li>\n<\/ul>\n<p><strong>PARIS, FRANCE, le 5 ao\u00fbt 2022\u00a0<\/strong>\u2013 Ipsen S.A. (Euronext : IPN\u00a0; ADR\u00a0: IPSEY) a annonc\u00e9 aujourd\u2019hui que sa filiale d\u00e9tenue indirectement \u00e0 100% Hibernia Merger Sub, Inc. (Acqu\u00e9reur) a prolong\u00e9 le d\u00e9lai de validit\u00e9 de son offre publique d\u2019achat annonc\u00e9e pr\u00e9c\u00e9demment en vue d\u2019acqu\u00e9rir la totalit\u00e9 des actions ordinaires en circulation (les Actions) d\u2019Epizyme, Inc. (NASDAQ : EPZM) (Epizyme) au prix de 1,45 $ par action, payable au d\u00e9tenteur en num\u00e9raire, sans int\u00e9r\u00eat et apr\u00e8s les retenues \u00e0 la source applicables, auquel s\u2019ajoute un Certificat de Valeur Garantie (CVG) par Action non-transf\u00e9rable, jusqu\u2019\u00e0 23h59, heure de l\u2019Est, le jeudi 11 ao\u00fbt 2022, sauf en cas de nouvelle prolongation. L\u2019offre publique d\u2019achat devait auparavant expirer une minute apr\u00e8s 23h59, heure de l\u2019Est, le lundi 8 ao\u00fbt 2022. Toutes\u00a0les autres modalit\u00e9s et conditions de l\u2019offre publique d\u2019achat restent inchang\u00e9es.<\/p>\n<p>Chaque CVG donne droit \u00e0 son d\u00e9tenteur \u00e0 un ou plusieurs paiements en num\u00e9raire, jusqu\u2019\u00e0 1,00 $ par CVG, sous r\u00e9serve de l\u2019atteinte de certaines \u00e9tapes dont les termes et les conditions sont d\u00e9crites dans l\u2019Offre d\u2019Achat dat\u00e9e du 12 juillet 2022 (ainsi que tout compl\u00e9ment ou toute modification \u00e0 l\u2019Offre d\u2019Achat) et dans la Lettre d\u2019Envoi (<em>Letter of Transmittal<\/em>) correspondante.<\/p>\n<p>L\u2019offre publique d\u2019achat a \u00e9t\u00e9 prolong\u00e9e en vue d\u2019accorder un d\u00e9lai suppl\u00e9mentaire afin que la condition relative \u00e0 l\u2019expiration ou \u00e0 la lev\u00e9e de la p\u00e9riode d\u2019attente (et toute prolongation de celle-ci) pr\u00e9vue par la loi Hart-Scott-Rodino Antitrust Improvements Act de 1976 telle qu\u2019amend\u00e9e (la \u00ab\u00a0condition HSR\u00a0\u00bb) soit satisfaite.<\/p>\n<p>Computershare Trust Company, N.A., d\u00e9positaire et agent payeur dans le cadre de l\u2019offre publique d\u2019achat, a indiqu\u00e9 qu\u2019\u00e0 17h00, heure de l\u2019Est, le 4 ao\u00fbt 2022, environ 42,256,760 Actions avaient \u00e9t\u00e9 valablement apport\u00e9es dans le cadre de l\u2019offre publique d\u2019achat et n\u2019ont pas \u00e9t\u00e9 valablement retir\u00e9es, soit environ 25% des Actions en circulation au 6 juillet 2022. Les actionnaires qui ont d\u00e9j\u00e0 apport\u00e9 leurs Actions dans le cadre de l\u2019offre publique d\u2019achat ne sont pas tenus d\u2019apporter \u00e0 nouveau leurs Actions ni de prendre d\u2019autre mesure \u00e0 la suite de la prolongation l\u2019offre publique d\u2019achat.<\/p>\n<p>L\u2019ex\u00e9cution de l\u2019offre publique d\u2019achat reste soumise \u00e0 d\u2019autres conditions d\u00e9crites dans la D\u00e9claration d\u2019Offre Publique d\u2019Achat sur l\u2019Annexe TO (Schedule TO), telle qu\u2019elle peut \u00eatre modifi\u00e9e ou compl\u00e9t\u00e9e, qui a \u00e9t\u00e9 enregistr\u00e9e par l\u2019Acqu\u00e9reur, Ipsen Biopharmaceuticals, Inc., Ipsen Pharma SAS et Ipsen S.A., aupr\u00e8s de la Securities and Exchange Commission (SEC) des \u00c9tats-Unis le 12 juillet 2022. Parmi ces conditions figure celle d\u2019avoir des Actions valablement apport\u00e9es et non valablement retir\u00e9es qui, ajout\u00e9es aux autres Actions (le cas \u00e9ch\u00e9ant) d\u00e9tenues par Ipsen Pharma SAS et ses filiales, repr\u00e9sentent au moins une Action de plus que 50 % du nombre total d\u2019Actions en circulation imm\u00e9diatement avant l\u2019expiration de l\u2019Offre (y compris toute prolongation).<\/p>\n<p>Les demandes de documents et questions concernant l\u2019offre publique d\u2019achat peuvent \u00eatre adress\u00e9es \u00e0 Georgeson LLC, l\u2019Agent d\u2019Information d\u00e9sign\u00e9 dans le cadre de l\u2019Offre Publique d\u2019Achat, par t\u00e9l\u00e9phone (gratuit) au (866) 203-9357 ou par e-mail \u00e0 l\u2019adresse\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EnOc8ycdQIMpl6bUUAQBTYbZfbDGcaMV0OvrZMZ8_LxinGMMpk8mv1PZXlocD9XLsd_XIySjopLu96eF-FExdDzEmiJcaFAJUKRxdlVlMmY=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong><u>epizyme@georgeson.com<\/u><\/strong><\/a>.<\/p>\n<p><strong>\u00c0 propos d\u2019Ipsen<\/strong><\/p>\n<p>Ipsen est une soci\u00e9t\u00e9 biopharmaceutique mondiale de taille moyenne focalis\u00e9e sur la mise au point de m\u00e9dicaments innovants en Oncologie, dans les Maladies rares et en Neurosciences. Avec un chiffre d\u2019affaires de 2,6 milliards d\u2019euros en m\u00e9decine de sp\u00e9cialit\u00e9 pour l\u2019exercice 2021, Ipsen vend des m\u00e9dicaments dans plus de 100 pays. Outre sa strat\u00e9gie d\u2019innovation externe, les efforts d\u2019Ipsen en mati\u00e8re de R&amp;D sont focalis\u00e9s sur ses plateformes technologiques diff\u00e9renci\u00e9es et innovantes situ\u00e9es au c\u0153ur de clusters mondiaux de la recherche biotechnologique ou en sciences de la vie (Paris-Saclay, France\u00a0; Oxford, Royaume-Uni\u00a0; Cambridge, \u00c9tats-Unis\u00a0; Shanghai, Chine). Ipsen compte environ 4\u00a0500\u00a0collaborateurs \u00e0 travers le monde et est cot\u00e9 en bourse \u00e0 Paris (Euronext\u00a0: IPN) et aux \u00c9tats-Unis \u00e0 travers un programme d\u2019<em>American Depositary Receipt<\/em>\u00a0(ADR\u00a0: IPSEY) sponsoris\u00e9 de niveau\u00a0I. Le site Internet d\u2019Ipsen est www.ipsen.com<\/p>\n<p><strong>Renseignements suppl\u00e9mentaires et sources d\u2019information<\/strong><\/p>\n<p>Le pr\u00e9sent communiqu\u00e9 ne constitue ni une offre d\u2019achat ni une sollicitation d\u2019une offre de vente d\u2019Actions. Le pr\u00e9sent communiqu\u00e9 est publi\u00e9 \u00e0 titre informatif uniquement. L\u2019offre publique d\u2019achat ne sera faite, et les apports en r\u00e9ponse \u00e0 l\u2019offre ne seront pas accept\u00e9s, en faveur ou pour le compte de porteurs d\u2019actions situ\u00e9s dans des juridictions dans lesquelles la r\u00e9alisation de l\u2019offre publique d\u2019achat ou l\u2019acceptation de celle-ci ne serait pas conforme aux lois de ces juridictions.<\/p>\n<p>L\u2019offre publique d\u2019achat est faite conform\u00e9ment \u00e0 une D\u00e9claration d\u2019Offre publique d\u2019Achat sur l\u2019Annexe TO (y compris une Offre d\u2019Achat, une Lettre d\u2019Envoi connexe et d\u2019autres documents relatifs \u00e0 l\u2019offre publique d\u2019achat) d\u00e9pos\u00e9e par l\u2019Acqu\u00e9reur, Ipsen Biopharmaceuticals, Inc., Ipsen Pharma SAS et Ipsen S.A. aupr\u00e8s de la SEC le 12 juillet 2022, dans sa version modifi\u00e9e ou compl\u00e9t\u00e9e de temps \u00e0 autre. En outre, le 12 juillet 2022, Epizyme a d\u00e9pos\u00e9 aupr\u00e8s de la SEC une D\u00e9claration de Sollicitation\/Recommandation en vertu de l\u2019Annexe 14D-9 (pouvant \u00eatre modifi\u00e9e ou compl\u00e9t\u00e9e de temps \u00e0 autre, la \u00ab D\u00e9claration de Sollicitation\/Recommandation \u00bb) concernant l\u2019offre publique d\u2019achat. IL EST CONSEILL\u00c9 AUX ACTIONNAIRES D\u2019EPIZYME DE LIRE L\u2019ANNEXE TO (COMPRENANT L\u2019OFFRE D\u2019ACHAT, LA LETTRE D\u2019ENVOI CORRESPONDANTE ET D\u2019AUTRES DOCUMENTS RELATIFS \u00c0 L\u2019OFFRE) ET L\u2019ANNEXE 14D-9, TELLES QU\u2019ELLES PEUVENT \u00caTRE MODIFI\u00c9ES OU COMPL\u00c9T\u00c9ES DE TEMPS \u00c0 AUTRE, AINSI QUE TOUT AUTRE DOCUMENT PERTINENT D\u00c9POS\u00c9 AUPR\u00c8S DE LA SEC, AVANT DE PRENDRE UNE D\u00c9CISION CONCERNANT L\u2019OFFRE PUBLIQUE D\u2019ACHAT, CAR ILS CONTIENDRONT DES INFORMATIONS IMPORTANTES SUR LA TRANSACTION PROPOS\u00c9E ET LES PARTIES. L\u2019Offre d\u2019Achat, la Lettre d\u2019Envoi correspondante et certains autres documents relatifs \u00e0 l\u2019offre publique d\u2019achat, ainsi que la D\u00e9claration de Sollicitation\/Recommandation, seront gratuitement mis \u00e0 disposition de tous les d\u00e9tenteurs d\u2019Actions. Les documents relatifs \u00e0 l\u2019offre publique d\u2019achat et la D\u00e9claration de Sollicitation\/Recommandation sont disponibles gratuitement sur le site Web de la SEC \u00e0 l\u2019adresse www.sec.gov.<\/p>\n<p><strong><u>Pour plus d\u2019informations :<\/u><\/strong><\/p>\n<p><strong>Contacts<\/strong><\/p>\n<p><strong><u>Investisseurs<\/u><\/strong><\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: middle\">   <strong>Adrien\u00a0Dupin de Saint-Cyr<\/strong><\/p>\n<p>      Responsable, Relations Investisseurs<\/p>\n<p>      +33 6 64 26 17 49   <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: middle\">   \u00a0   <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: middle\">\u00a0<\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p><strong><u>M\u00e9dias<\/u><\/strong><\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: top\">   <strong>Joanna Parish<\/strong><\/p>\n<p>      Directrice Communication Globale Franchise, Oncologie<\/p>\n<p>      44 7840 023 741   <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: top\">   <strong>Ioana Piscociu<\/strong><\/p>\n<p>      Responsable senior, Relations Global Media<\/p>\n<p>      +33 6 69 09 12 96   <\/td>\n<\/tr>\n<\/table>\n<p id=\"gnw_attachments_section-header\"><strong>Pi\u00e8ce jointe<\/strong><\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0bDvfHEaUGXw98Q8y3nvDFltoSc8g6bEHxXoNrhkOtGe54FU2bLKa2JusOemZNQD057E9TF2F1UaQsPCESmLFIfBAA8J38UVim5o9xTKYDHwCw_gN4T5xEYDnbsO8Hhs7iElvS6NILCdT1LyWQDbXgipjYht8cqahOZ1nVad9red_qOKrlRXCA6R3nPKEigYZINQInhi3xThbXoBuguKwIcFplWTc2l-Z6VE_GkaklBg5yNpSWJHoF9siVTWOYjlEwoejErC5PvQoj7aJW5kQQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-dEpizyme-Inc.-au-11-aout-2022\">Ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-dEpizyme-Inc.-au-11-aout-2022<\/a><\/li>\n<\/ul>\n<p><img src='https:\/\/ml-eu.globenewswire.com\/media\/NTc4YmI4NTktODRjMS00MDYzLTg1YTItOGUwMDI4ZTUzMDlkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png' \/><\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[],"tags":[],"class_list":["post-1688","press_release","type-press_release","status-publish","hentry","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ipsen annonce l\u2019extension de son offre publique d\u2019achat des actions d\u2019Epizyme, Inc. au 11 ao\u00fbt 2022 - Annual Report<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen annonce l\u2019extension de son offre publique d\u2019achat des actions d\u2019Epizyme, Inc. au 11 ao\u00fbt 2022 - Annual Report\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Annual Report\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-19T17:52:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ml-eu.globenewswire.com\/media\/NTc4YmI4NTktODRjMS00MDYzLTg1YTItOGUwMDI4ZTUzMDlkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/\",\"name\":\"Ipsen annonce l\u2019extension de son offre publique d\u2019achat des actions d\u2019Epizyme, Inc. au 11 ao\u00fbt 2022 - Annual Report\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/NTc4YmI4NTktODRjMS00MDYzLTg1YTItOGUwMDI4ZTUzMDlkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"datePublished\":\"2022-08-05T07:00:00+00:00\",\"dateModified\":\"2023-05-19T17:52:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/#primaryimage\",\"url\":\"https:\/\/ml-eu.globenewswire.com\/media\/NTc4YmI4NTktODRjMS00MDYzLTg1YTItOGUwMDI4ZTUzMDlkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\",\"contentUrl\":\"https:\/\/ml-eu.globenewswire.com\/media\/NTc4YmI4NTktODRjMS00MDYzLTg1YTItOGUwMDI4ZTUzMDlkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/annualreport\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen annonce l\u2019extension de son offre publique d\u2019achat des actions d\u2019Epizyme, Inc. au 11 ao\u00fbt 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#website\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/\",\"name\":\"Annual Report\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#organization\",\"name\":\"Annual Report\",\"url\":\"https:\/\/www.ipsen.com\/annualreport\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"Annual Report\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat des actions d\u2019Epizyme, Inc. au 11 ao\u00fbt 2022 - Annual Report","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat des actions d\u2019Epizyme, Inc. au 11 ao\u00fbt 2022 - Annual Report","og_url":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/","og_site_name":"Annual Report","article_modified_time":"2023-05-19T17:52:08+00:00","og_image":[{"url":"https:\/\/ml-eu.globenewswire.com\/media\/NTc4YmI4NTktODRjMS00MDYzLTg1YTItOGUwMDI4ZTUzMDlkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/","url":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/","name":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat des actions d\u2019Epizyme, Inc. au 11 ao\u00fbt 2022 - Annual Report","isPartOf":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/ml-eu.globenewswire.com\/media\/NTc4YmI4NTktODRjMS00MDYzLTg1YTItOGUwMDI4ZTUzMDlkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","datePublished":"2022-08-05T07:00:00+00:00","dateModified":"2023-05-19T17:52:08+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/#primaryimage","url":"https:\/\/ml-eu.globenewswire.com\/media\/NTc4YmI4NTktODRjMS00MDYzLTg1YTItOGUwMDI4ZTUzMDlkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png","contentUrl":"https:\/\/ml-eu.globenewswire.com\/media\/NTc4YmI4NTktODRjMS00MDYzLTg1YTItOGUwMDI4ZTUzMDlkLTEwMTA5NDM=\/tiny\/Ipsen-SA.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/annualreport\/fr\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-des-actions-depizyme-inc-au-11-aout-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/annualreport\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat des actions d\u2019Epizyme, Inc. au 11 ao\u00fbt 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/annualreport\/#website","url":"https:\/\/www.ipsen.com\/annualreport\/","name":"Annual Report","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/annualreport\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/annualreport\/#organization","name":"Annual Report","url":"https:\/\/www.ipsen.com\/annualreport\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/sites\/3\/2023\/12\/07162703\/Latest_Ipsen-logo_168x48.svg","caption":"Annual Report"},"image":{"@id":"https:\/\/www.ipsen.com\/annualreport\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release\/1688","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/users\/1"}],"version-history":[{"count":0,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/press_release\/1688\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/media?parent=1688"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/categories?post=1688"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/annualreport\/fr\/wp-json\/wp\/v2\/tags?post=1688"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}